Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Almotriptan Malate

FDA-approved product (tablet, oral), marketed as Almotriptan Malate, Axert.

Registered studies
16
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Almotriptan Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin (5ht1) agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

16registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Almotriptan Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Almotriptan Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

    NCT05854992 · start 2022-07-05

    Registered record
    Registry ID
    NCT05854992
    Conditions
    Migraine; Cardiovascular Diseases; Pregnancy
    Interventions
    Acute migraine treatment with any prescribed triptans; Standard of care management of acute migraine without triptans
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-07-05
    Completion
    2024-11-01
    Enrolment
    68,419

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Cardiovascular Diseases; Pregnancy
    InterventionAcute migraine treatment with any prescribed triptans; Standard of care management of acute migraine without triptans
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine

    NCT05214001 · start 2022-06-30

    Registered record
    Registry ID
    NCT05214001
    Conditions
    Migraine With Aura; Migraine Without Aura
    Interventions
    Almotriptan 12.5 Mg Oral Tablet; Ubrogepant 50Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-06-30
    Completion
    2024-04-15
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With Aura; Migraine Without Aura
    InterventionAlmotriptan 12.5 Mg Oral Tablet; Ubrogepant 50Mg Tab
    PhasePhase 4
    Registry statusTerminated

  • ACT Therapy for HF Migraine

    NCT03461874 · start 2018-03-15

    Registered record
    Registry ID
    NCT03461874
    Conditions
    Migraine Without Aura
    Interventions
    Education of patients; ACT; Pharmacological prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-03-15
    Completion
    2022-12-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Without Aura
    InterventionEducation of patients; ACT; Pharmacological prophylaxis
    PhaseNot applicable
    Registry statusCompleted

  • A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data

    NCT01381523 · start 2010-11

    Registered record
    Registry ID
    NCT01381523
    Conditions
    Migraine Disorders
    Interventions
    Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap); Single-entity oral triptans
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-11
    Completion
    2011-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionCombination therapy with sumatriptan and naproxen sodium (SumaRT/Nap); Single-entity oral triptans
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy

    NCT01381497 · start 2010-03

    Registered record
    Registry ID
    NCT01381497
    Conditions
    Migraine Disorders
    Interventions
    Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap); Triptan monotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionCombination therapy of sumatriptan and naproxen sodium (SumaRT/Nap); Triptan monotherapy
    PhaseNot recorded
    Registry statusCompleted

  • Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?

    NCT01086358 · start 2009-09

    Registered record
    Registry ID
    NCT01086358
    Conditions
    Workplace Migraine Treatment
    Interventions
    Triptan; Treximet 85Mg-500Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2016-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWorkplace Migraine Treatment
    InterventionTriptan; Treximet 85Mg-500Mg Tablet
    PhasePhase 4
    Registry statusCompleted

  • Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine

    NCT01435941 · start 2009-09

    Registered record
    Registry ID
    NCT01435941
    Conditions
    Migraine Disorders
    Interventions
    Non-steroidal anti-inflammatory drug (NSAID); Triptan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-09
    Completion
    2011-02
    Enrolment
    11,249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionNon-steroidal anti-inflammatory drug (NSAID); Triptan
    PhaseNot recorded
    Registry statusCompleted

  • Treximet ™ Pharmacy Budget Impact Model Database Validation Study

    NCT01332500 · start 2009-07

    Registered record
    Registry ID
    NCT01332500
    Conditions
    Migraine Disorders
    Interventions
    Sumatriptan/Naproxen combination; other oral triptans
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-03
    Enrolment
    61,737

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionSumatriptan/Naproxen combination; other oral triptans
    PhaseNot recorded
    Registry statusCompleted

  • Standardized sTudy With Almotriptan in eaRly Treatment of Migraine

    NCT00725140 · start 2008-06

    Registered record
    Registry ID
    NCT00725140
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-06
    Completion
    2009-07
    Enrolment
    501

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Detoxification and Treatment of Subjects With Medication Overuse Headache

    NCT00432549 · start 2007-01

    Registered record
    Registry ID
    NCT00432549
    Conditions
    Analgesic Rebound Headache
    Interventions
    Almotriptan; Topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-01
    Completion
    2007-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnalgesic Rebound Headache
    InterventionAlmotriptan; Topiramate
    PhasePhase 4
    Registry statusUnknown

  • A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

    NCT00257010 · start 2005-12

    Registered record
    Registry ID
    NCT00257010
    Conditions
    Migraine
    Interventions
    Almotriptan Malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2007-12
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionAlmotriptan Malate
    PhasePhase 3
    Registry statusCompleted

  • Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

    NCT00210496 · start 2005-06

    Registered record
    Registry ID
    NCT00210496
    Conditions
    Migraine; Classic Migraine; Common Migraine
    Interventions
    topiramate; almotriptan malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    2007-06
    Enrolment
    406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Classic Migraine; Common Migraine
    Interventiontopiramate; almotriptan malate
    PhasePhase 4
    Registry statusCompleted

  • A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache

    NCT00210509 · start 2004-11

    Registered record
    Registry ID
    NCT00210509
    Conditions
    Migraine
    Interventions
    almotriptan malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-11
    Completion
    2005-06
    Enrolment
    378

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    Interventionalmotriptan malate
    PhasePhase 4
    Registry statusCompleted

  • The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain

    NCT00212823 · start 2004-06

    Registered record
    Registry ID
    NCT00212823
    Conditions
    Migraine
    Interventions
    almotriptan malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-02
    Enrolment
    1,450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    Interventionalmotriptan malate
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers

    NCT00208065 · start 2004-05

    Registered record
    Registry ID
    NCT00208065
    Conditions
    Migraine; Sinusitis
    Interventions
    almotriptan or pseudoephedrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2005-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Sinusitis
    Interventionalmotriptan or pseudoephedrine
    PhasePhase 4
    Registry statusCompleted